This study confirmed decrease in SEC13 expression with all cancer stages (II, III, IV); while SMAD7 tended to be especially highly expressed in GC patients with stage IV, which could explain the significant negative correlation between SEC13 and SMAD7. The gene discussed is SMAD7; the disease is gastric cancer.